Benzinga | May 7, 2021 06:07AM EDT

Amneal Pharmaceuticals Q1 Adj. EPS $0.20 Beats $0.18 Estimate, Adj. EBITDA $126M, Sales $493.00M Miss $515.34M Estimate; Reaffirms FY21 Guidance

Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.18 by 11.11 percent. This is unchanged from the same period last year. The company reported quarterly sales of $493.00 million which missed the analyst consensus estimate of $515.34 million by 4.34 percent. This is a 1.11 percent decrease over sales of $498.53 million the same period last year.